How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms

How I treat: Thrombotische/thromboembolische Komplikationen bei Patienten mit Myeloproliferativen Neoplasien

Steffen Koschmieder

1 Department of Medicine (Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation), Faculty of Medicine, RWTH Aachen University, Aachen, Germany

Abstract

Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are at increased risk for arterial and venous thrombosis/thromboembolism. In particular, the risk of splanchnic venous thrombosis, such as portal vein thrombosis or Budd–Chiari syndrome, is significantly higher in patients with MPN than in the normal population. At the same time, MPN patients are at increased risk for severe bleeding. Therefore, the treatment of patients with MPN must be based on their suspected probability of thrombosis/thromboembolism and bleeding. For this purpose, patient and MPN-specific risk factors are used. Patients at expected high risk of thrombosis should receive adequate primary or secondary thromboprophylaxis in addition to cytoreductive therapy. This may consist of antiplatelet agents and/or anticoagulant agents and must be balanced with the individual bleeding risk. The goal is to increase the quality of life and life span of patients with MPNs by preventing (re-)thrombosis and severe bleeding.

Keywords
► myeloproliferative neoplasms (MPNs)
► thrombosis/thromboembolism
► therapy
► anticoagulation
► cytoreduction
► polycythemia vera (PV)
► essential thrombocythemia (ET)
► primary myelofibrosis (PMF)

Zusammenfassung


Address for correspondence Prof. Dr. med. Steffen Koschmieder, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Medizinische Fakultät, Uniklinik RWTH Aachen, Pauwelsstr. 30, D-52074 Aachen, Germany (e-mail: skoschmieder@ukaachen.de).
Introduction

Philadelphia-negative myeloproliferative neoplasms (MPNs) are chronic hematological malignancies. They share a common pathogenesis, which derives from the JAK-STAT pathway activation through the presence of a JAK2, calreticulin (CALR), or the myeloproliferative leukemia virus oncogene (MPL) mutation in the hematopoietic stem and progenitor cells (HSPCs) and extramedullary hematopoiesis causing splenomegaly. The classical Ph neg MPN subtypes include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and their diagnosis criteria have been revised by the World Health Organization (WHO) in 2016. Common symptoms include those generally found in MPN such as fatigue, early satiety and abdominal discomfort, inactivity, concentration problems, constitutional symptoms (fever, night sweats, and weight loss), bone pain, but also aquagenic pruritus, which designates pruritus upon contact with water. And during the course of disease, patients may acquire complications such as thrombotic/thromboembolic events, severe hemorrhage, or disease progression to post-PV-myelofibrosis (post-PV-MF), or post-ET-myelofibrosis (post-ET-MF), or even acute leukemia. Treatment of patients with MPN aims at preventing these complications through various cytoreductive agents and disease modulation. However, these therapies are noncurative, and while allogeneic stem cell transplantation (SCT) may be curative, this option is associated with significant morbidity and mortality and is thus reserved for the minority of patients with a poor prognosis. Patients who have encountered thrombosis/thromboembolism or severe bleeding before or during the course of an MPN are at high risk for recurrent thrombosis/thromboembolism. Real-world analyses from MPN registries have found the frequency of thrombosis/thromboembolism and major bleeding events in MPN patients to be 11 to 33% and 2 to 8%, respectively. The location of the thrombotic events differed significantly among the MPN subtypes PV, ET, and PMF. In particular, splanchic vein thrombosis, including portal vein thrombosis and Budd–Chiari syndrome, is by far more frequent in MPN than in non-MPN patients. Mechanisms of thrombosis in MPN include increased numbers and activation of blood cells and endothelial cells, JAK2V617F-induced inflammation and integrin-mediated adhesiveness, as well as tissue factor-containing microparticles, and activation of procoagulant factors (all reviewed in Kroll et al10). In addition, neutrophil extracellular trap formation has been implicated in thrombosis/thromboembolism development in mice and MPN patients expressing JAK2V617F.11

Therefore, since MPNs are chronic diseases, the requirement for anticoagulant and/or antiplatelet treatment is typically lifelong. And in patients with thrombosis/thromboembolism in whom no proper cause can be found, an MPN needs to be ruled out, especially if they also have abnormal blood cell counts and/or splenomegaly. The incidence of thrombosis/thromboembolism peaks around the diagnosis of an MPN, suggesting that the thrombosis/thromboembolism itself often leads to the MPN diagnosis. Conversely, the incidence of severe bleeding is low before the MPN diagnosis but is increased thereafter, which suggests that therapy of MPN and/or progression contributes to bleeding in these patients. In the following, I summarize my approach to the management of thrombosis/thromboembolism in patients with MPN, including specific recommendations for PV and ET (Fig. 1). Current treatment recommendations have recently been revised (see www.onkopedia.com/de and ELN recommendations). In addition to these specific recommendations, cessation of smoking and adequate physical exercise should be advised to all MPN patients.

Polycythemia Vera

PV is characterized by expansion of all three hematopoietic lineages in the bone marrow (granulocytic, erythrocytic, and megakaryocytic) and peripheral blood (neutrophilia, erythrocytosis, and thrombocytosis), the presence of a JAK2 mutation, and a subnormal erythropoietin level. Its incidence ranges around 1/100,000 inhabitants, but its prevalence is considerably greater due to the long course of the disease in most patients. The exon 14 JAK2 mutation is present in approximately 96% of patients and translates to the mutant JAK2V617F oncoprotein. The exon 12 JAK2 mutation is present in roughly 2 to 3% of patients and is associated with a more exclusive expansion of red cell mass, also termed polycythemia vera rubra. Common symptoms include those generally found in MPNs (see above), with aquagenic pruritus being more frequent in PV than in the other MPN subtypes. The risk of progression to post-PV-MF and acute leukemia is 9 to 21% and 3 to 10%, respectively, and mean survival of PV patients ranges from 10.8 to 27.8 years. Photographic documentation of disease.
Controlled randomized clinical trials have demonstrated enhanced thrombosis-free survival for both low-dose acetylsalicylic acid (ASA) treatment and phlebotomies. Thus, when the diagnosis of PV is made, all patients should receive both of these therapeutic interventions, unless there are contraindications (which are rare). In addition, the so-called “high-risk” PV patients, i.e., those aged over 60 years and/or those that have experienced a thrombosis/thromboembolism, should additionally receive cytoreductive treatment. In addition, progression of myeloproliferation (e.g., with development of relevant leukocytosis, thrombocytosis, and/or splenomegaly) or intolerance to phlebotomies may also be indications for cytoreduction. However, both the type of cytoreductive therapy and the anticoagulant agent used for thrombosis/thromboembolism treatment have to be chosen individually according to the patient’s needs:

- High-risk PV patients that have not yet experienced any thrombosis/thromboembolism should receive hydroxyurea or ropinginterferon α (ropegIFNa) as first-line cytoreductive treatment (both options currently approved in Europe) or ruxolitinib as second-line treatment. Further, nonapproved drugs include busulfan and other IFNa compounds. Quite often, phlebotomies will not be necessary anymore when cytoreduction has been initiated. However, ASA should not be discontinued, even when phlebotomies are no longer necessary.
- High-risk PV patients that have experienced an arterial thrombosis/thromboembolism such as a stroke or myocardial infarction should receive life-long ASA treatment in addition to cytoreductive treatment (see above), along with the usual further secondary prophylaxis (ACE or AT receptor inhibitors, statins, etc.). Vitamin K antagonists (VKAs) may be indicated in such patients, either if they suffer from repeated arterial events despite ASA medication or if they have additional thrombophilic conditions such as antiphospholipid syndrome (APS). Non-vitamin K oral anticoagulants (NOACs) may also be given in patients where VKA cannot be given, but not in those with APS and MPN. NOAC use is currently not recommended in patients with APS, with the European Medicines agency (EMA) issuing a warning (https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-april-2019-prac-meeting_en.pdf) that “direct acting oral anticoagulants (DOACs) including rivaroxaban/apixaban/edoxaban/dabigatran etexilate are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome,” particularly those with threefold positivity for lupus anticoagulant, anticardiolipin antibodies, and anti-B2-glycoprotein antibodies. The most recent summaries of product characteristics of the approved NOACs now also advise against the use of NOACs in all patients with APS.
- High-risk PV patients having experienced venous thrombosis/thromboembolism (VTE) should receive proper antiplatelet treatment (ASA) and anticoagulant therapy (VKA) if indicated.

---

**Fig. 1** Recommendations for antiplatelet and anticoagulant therapy as well as cytoreductive treatment in PV and ET. ASA, acetylsalicylic acid; ET, essential thrombocythemia; PV, polycythemia vera; VKA, vitamin K antagonist; VTE, venous thromboembolism. See the text for more detailed explanations. aVKA is the first choice, non-vitamin K antagonists (NOACs) are the second choice; stop ASA if starting VKA or NOACs. bPhlebotomy aims at keeping hematocrit below 45%; phlebotomies may no longer be necessary after starting cytoreductive therapy.

---

a According to international convention, the term “low-dose ASA” designates doses between 75 to 100 mg/d.
Essential Thrombocythemia

The hallmark of ET is thrombocytosis, coupled with megakaryocytic hyperplasia of the bone marrow and the presence of a clonal marker. Genetic analysis of driver mutations revealed the presence of a JAK2 V617F, CALR, and MPL mutation in up to 50–60, 20–25, and 5% of ET patients, leaving approximately 10 to 15% “triple-negative” patients, who have other mutations or chromosomal aberrations. The incidence of ET has been calculated to be approximately 2–3/100,000 inhabitants, a slightly higher rate than previously reported, due to the availability of the genetic markers, allowing exclusion of reactive thrombocytosis cases. Symptoms include those mentioned in the Introduction, but splenomegaly, itching, and weight loss are less common in ET than in PV and PMF. Progression to post-ET-MF and acute leukemia is rare, especially when considering “true ET” (ET diagnosed according to the WHO 2016 criteria) cases by separating pre-PMF cases. Patients with “true ET” have a normal life expectancy.

After making the diagnosis of ET, physicians should estimate the risk of the individual patient with ET (low- vs. intermediate- vs. high-risk patients, as defined by the DGHO for ET; see below), since this will define the treatment recommendation in this patient. Given the normal life expectancy of the patients with ET, this risk in the clinical setting designated the risk for thrombotic and severe bleeding events.

Low-risk ET patients, as defined by the DGHO (i.e., those aged < 60 years, without previous thrombosis/thromboembolism or severe hemorrhage, and in whom platelet counts have remained below 1,500/nL), typically do not need ET-specific treatment, and an approach of watchful waiting is indicated. The use of antiplatelet agents has been the matter of some debate. However, neither the current German recommendations on the management of ET by the DGHO (www.onkopedia.com/de), nor the European LeukemiaNet (ELN) recommendations, nor the NCCN guidelines favor the general use of ASA in all patients with ET. Therefore, accordingly, I typically do not use ASA in most low-risk patients with ET. Conversely, “all patients with ET should be managed with low-dose aspirin if microvascular disturbances are present,” and this is also my current practice.

Intermediate-risk ET patients, as defined by the DGHO, are those who have first-degree relatives with cardiovascular disease, putting them at a higher risk of cardiovascular disease. Although randomized trials of ASA in ET patients are lacking in general, current treatment guidelines recommend that intermediate-risk ET patients should receive low-dose ASA.

High-risk ET patients, as defined by the DGHO and ELN, are those patients that are aged over 60 years and/or have experienced thrombosis/thromboembolism or severe hemorrhage previously, and/or in whom platelet counts have exceeded 1500/nL. These patients are at a higher risk of developing thrombosis/thromboembolism and/or severe bleeding and therefore require cytoreductive therapy, in addition to ASA. Another reason to initiate cytoreductive therapy in such patients is the presence of significant bleeding risk due to platelet dysfunction and/or acquired von Willebrand syndrome (AVWS), as defined by a von Willebrand factor (VWF):ristocetin cofactor activity/VWF antigen ratio of <0.7 (see below and review in Appelmann et al). Both platelet dysfunction and AVWS are more prevalent in patients with excessive than normal platelet counts but can occur even in patients with normal platelet counts. Therefore, I routinely perform screening for AVWS in MPN patients before initiating antiplatelet treatment. Nevertheless, it should be kept in mind that AVWS may be due to deficiency in high-molecular weight VWF multimers, and this requires confirmation by multimeric analysis of VWF. Finally, the presence of an AVWS does not predict bleeding, thus, the decision whether or not to withhold ASA is based primarily on clinical judgment of the bleeding risk, taking all of the above factors into account.

Hydroxyurea and anagrelide are approved first-line options for the treatment of high-risk ET. IFNa therapy is off-label, but is recommended in young patients, especially women who are or wish to become pregnant. Busulfan is a possible second- or third-line option, particularly in older patients.
patients. In addition, the following recommendations for antiplatelet and anticoagulant therapy exist.

ET patients with previous or concurrent arterial thrombosis/thromboembolism should receive standard management as those without ET. Life-long ASA as secondary prophylaxis is required. Exceptional cases may necessitate VKA treatment, such as those with recurrent arterial thrombosis/thromboembolism despite antiplatelet agents or those with APS. In patients with ET and myocardial infarction undergoing percutaneous coronary intervention with direct-platelet inhibition, using ASA and clopidogrel, there was no difference in the responsiveness to these two drugs when compared with non-ET patients. However, ASA-insensitive thromboxane biosynthesis has been described in ET patients, assessed by thromboxane B2 determination ex vivo, most likely due to accelerated production of new platelets. This was also confirmed in a second study. Both twice-daily instead of once-daily ASA and/or cyto reduces therapy led to inhibition of cyclooxygenase-1 and platelet aggregation in vitro, but it is still unclear whether twice-daily ASA can safely decrease the risk of thrombosis in ET patients. Therefore, twice-daily ASA can be considered but is not currently recommended in patients with ET requiring ASA.

Importantly, patients with a high bleeding risk, including those with a VWF:ristocetin cofactor activity of less than 30% should not receive ASA, until their bleeding risk is lowered, e.g., by cyto reduces therapy. When used in combination with anagrelide, antiplatelet agents must be used with caution due to the higher bleeding risk.

ET patients with previous or concurrent venous thrombosis/VTE should be treated as their counterparts without ET. Again, anticoagulant treatment must be used with caution due to the higher bleeding risk, especially in patients with AVWS or those concomitantly treated with anagrelide, which has been shown to carry an elevated risk of bleeding when combined with antiplatelet agents. The duration of anticoagulant therapy in ET is still unsettled, particularly in light of the lower incidence of thrombosis/thromboembolism than in PV. However, in the absence of firm data, the same caution against co-administration of antplatelet and anticoagulant therapy and the same duration of anticoagulant treatment are recommended as stated above for PV.

Recently, a new scoring system, the so-called “IPSET-thrombosis” score, has retrospectively been defined to classify patients with ET according to their individual risk of thrombosis. According to this score, patients receive 1 point each in the case of an age over 60 years or cardiovascular risk factors, and 2 points each in the case of previous thrombosis or JAK2 V617F positivity. A sum of 0–1 points, 2, or ≥3 points defines low, intermediate, or high thrombosis risk, respectively. The National Comprehensive Cancer Network (NCCN) guidelines recommend ASA to be “considered to reduce the risk of thrombotic complications for patients with very low risk, low-risk, or intermediate-risk ET” according to the IPSET-thrombosis score. It is conceivable that, in the future, we will increasingly use biologic factors such as JAK2 V617F positivity for our therapeutic decisions, e.g., ASA use in JAK2 V617F-positive ET, as has been proposed. However, most treatment recommendations have not yet firmly incorporated the IPSET-thrombosis risk subgroups.

**Primary Myelofibrosis and Post-PV-MF and Post-ET-MF**

MPNs with myelofibrosis are further categorized into the following subtypes: prefibrotic PMF (pre-PMF), overt PMF, post-PV-MF, and post-ET-MF. For each of these subtypes, specific diagnostic criteria have been established. However, since PMF has only recently been subdivided into pre-PMF and overt PMF (WHO 2016), less information is available on these individual subtypes. However, it is clear for all four MF subtypes that patients with MF have a shorter survival as compared with age-matched controls and that they suffer from more severe symptoms, particularly weight loss, splenomegaly-related early satiety, and anemia-associated symptoms. It is less clear to what extent these patients are at risk for thrombosis/thromboembolism and bleeding. A recent analysis of the German MPN registry found considerable differences between PMF, post-PV-MF, and post-ET-MF for the rate of thrombosis/thromboembolism and severe bleeding.

Risk scoring in MF, including the Dynamic International Prognostic Scoring System (DIPSS), is based upon clinical and molecular parameters and predicts survival. For PMF, several scores have been designed and validated, but the DIPSS score is used most commonly for therapy stratification. Based on this score, intermediate-2 (int-2) and high-risk MF patients should undergo eligibility screening for allogeneic SCT (allo-SCT). If allo-SCT is not performed, symptomatic MF patients can be treated with ruxolitinib to alleviate their symptoms and possibly enhance survival. In patients with post-PV- or post-ET-MF, the Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC score) should be calculated, and those patients with an int-2 or high-risk MYSEC score should be treated in the same way as described above for PMF patients.

No general recommendation for ASA use or anticoagulant treatment is available for MF patients. Thus, these patients are being treated on an empirical basis, with pre-PMF patients most often being treated according to the ET algorithm, due to the similarity of risk factors in pre-PMF and ET. Since thrombosis/thromboembolism and bleeding represent significant risks in MF (up to 62% of patients with post-PMF-MF had experienced a thromboembolic episode), careful screening for cardiovascular risk factors and thrombosis/thromboembolism is necessary in all MF patients. Additional caution for bleeding events is warranted in patients with MF-associated hematopoietic insufficiency, particularly in thrombocytopenic patients, and those with AVWS (see above for ET).

**Concluding Remarks**

Patients with MPNs are at high risk of developing thromboembolic/thrombotic complications. At the same time, they are also prone to severe bleeding. These risks are influenced by age and the presence of additional cardiovascular risk factors, but also by the MPN subtype and the genetic mutational profile. Thus, first of all, a correct diagnosis must be established, and all
relevant medical history, concomitant medication, and family history need to be taken into account. Then, disease-specific risk group allocation needs to be performed, including calculation of scores for overall survival (such as DIPSS and MYSEC scores in primary and secondary myelofibrosis) and for thrombosis-free survival (e.g., conventional risk factor assessment in PV or ET and IPSET-thrombosis score in ET). The risk group allocation for the individual patient helps to decide upon whether and which type of treatment is indicated. Both primary prophylaxis and secondary prophylaxis approaches for thrombosis/thromboembolism and severe hemorrhage are established for specific disease scenarios, and these should be initiated and combined with cytoreductive therapy as needed, according to current national and international treatment recommendations. Finally, since MPNs are chronic diseases, regular monitoring of the thromboembolic/thrombotic risk as well as their risk of bleeding is necessary to maintain an optimal survival span and quality of life of our patients.

Conflicts of Interest
S.K. reports research funding from Novartis, Janssen, AOP Orphan Pharmaceuticals AG, and Bristol-Myers Squibb, as well as consultancy honoraria from Novartis, Incyte/Ariad, Bristol-Myers Squibb, AOP Orphan Pharmaceuticals AG, Pfizer, Celgene, Bayer, Roche, CTI, and Shire.

References